 |
|
Management of Iliofemoral Thrombosis in a Pregnant Patient With Heparin Resistance
Sonia S. Anand, MD, MSc, FRCPC;
Scott Brimble, MD;
Jeffrey S. Ginsberg, MD, FRCPC
Arch Intern Med. 1997;157(7):815-816.
Abstract
A 25-year-old primiparous woman presented at 30 weeks of gestation with suspected deep vein thrombosis of the left leg. Results of initial noninvasive tests were not in agreement and subsequent venographic findings revealed left iliac vein thrombosis. Treatment was initiated with continuous intravenous unfractionated heparin sodium for 3 days and then switched to twice-daily subcutaneous unfractionated heparin. Unfractionated heparin, 60 000 U per 24 hours, was required to maintain the activated partial thromboplastin time within the therapeutic range, which posed problems because of large volumes of injection. Therapy with subcutaneous low-molecular-weight heparin was successfully substituted and the patient had an uncomplicated full-term delivery.
Arch Intern Med. 1997;157:815-816
Author Affiliations
From the Department of Medicine, McMaster University, Hamilton, Ontario.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Parenteral Anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Hirsh et al.
Chest 2008;133:141S-159S.
ABSTRACT
| FULL TEXT
Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy
Greer and Nelson-Piercy
Blood 2005;106:401-407.
ABSTRACT
| FULL TEXT
Heparin and Low-Molecular-Weight Heparin: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Hirsh and Raschke
Chest 2004;126:188S-203S.
ABSTRACT
| FULL TEXT
Heparin and Low-Molecular-Weight Heparin Mechanisms of Action, Pharmacokinetics, Dosing, Monitoring, Efficacy, and Safety
Hirsh et al.
Chest 2001;119
:64S-94S.
FULL TEXT
|
